Researchers have identified a new peptide from cone snail venom that could lead to safer pain treatments. The substance, known as AoIA, significantly reduced inflammation-induced pain in animal models after a simple injection under the skin. This finding offers a potential new path for developing non-opioid painkillers that do not carry the risks associated with traditional opioids.
The research team, led by Harald Sitte from the Medical University of Vienna, found that AoIA specifically inhibits the noradrenaline transporter. By blocking this transporter, the peptide helps the body’s own pain-inhibiting mechanisms. This mechanism is distinct from opioids, which target opioid receptors in the brain.
The scientists collaborated with Eric Xu at the Shanghai Institute of Materia Medica to map the three-dimensional structure of the human noradrenaline transporter. Using cryo-electron microscopy, they determined how the peptide binds to the transporter. This allowed them to understand why AoIA is selective for noradrenaline and does not affect closely related proteins for serotonin or dopamine. The high selectivity makes the peptide a promising candidate for drug development.
Related: AI IDs New Drug Target in Solid Tumors
The study, published in the journal Nature Structural and Molecular Biology, notes that cone snail venoms have long been a source of active substances. A drug developed from a cone snail peptide is already in clinical use for chronic pain. The current research expands this field by detailing the structural basis of AoIA’s action.
A distinct advantage over previous treatments
The primary distinction between this new peptide and older cone snail-derived treatments is the method of administration. Previous peptides, such as MrIA, required direct injection into the cerebrospinal fluid to be effective. AoIA, however, exerts its effect following subcutaneous administration beneath the skin. This peripheral administration method is significantly gentler to use and easier for medical professionals to administer.
Further tests in mouse models showed that AoIA only reduced pain during the inflammation phase. It had no effect on models of acute pain. The study also confirmed that the peptide does not cause sedation or impair motor coordination, which are common side effects of other pain medications.
Related: Is High Uric Acid A Warning Sign Of Kidney Disease?
“Our results show how a naturally occurring peptide specifically influences the noradrenaline transporter and can thereby support the body’s own pain-inhibiting mechanisms,” Sitte said. “The fact that we were able to demonstrate both its mode of action at the molecular level and its pain-relieving effect following subcutaneous administration in an animal model lays an important foundation for the development of new non-opioid pain medications that are significantly easier to administer.”
The research involved scientists from Austria, China, Australia, Turkey, and the Philippines. The study concludes that while the results are promising, further preclinical and clinical studies are required before the peptide can be used in humans.
